Amarantus Bioscience

Amarantus BioScience Holdings (OTCQB: AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases. AMBS owns the rights to Engineered Skin Substitute program, a regenerative medicine-based approach for treating severe burns with full thickness autologous skin grown in tissue culture. ESS is entering Phase 2 clinical studies under a CRADA agreement with the US Army, and is also preparing a pivotal development program for rare pediatric disease Giant Congenital Melanocytic Nevi. AMBS' also has licensing rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor and is developing MANF-based products as treatments for brain and ophthalmic disorders. AMBS' Diagnostics division owns the rights to MSPrecise®, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro). AMBS also owns the discovery of neurotrophic factors (PhenoGuard™) that led to MANF's discovery. Amarantus is a Founding Member of Global Brain Health Coalition (GBHC). The GBHC mission is to become the leading global voice for brain health awareness and empowerment by converging science, clinical research and impact. The Company believes that TBI-induced neurodegeneration represents a new frontier of clinical research which may ultimately allow for commonalities between chronic degenerative disorders.